Hims & Hers Health, Inc. $HIMS Shares Bought by US Bancorp DE

US Bancorp DE raised its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 265.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,917 shares of the company’s stock after acquiring an additional 19,561 shares during the quarter. US Bancorp DE’s holdings in Hims & Hers Health were worth $1,342,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Northern Trust Corp grew its position in Hims & Hers Health by 19.5% in the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after acquiring an additional 397,310 shares in the last quarter. Yong Rong HK Asset Management Ltd boosted its stake in shares of Hims & Hers Health by 41.2% in the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock valued at $70,920,000 after buying an additional 700,100 shares during the period. Nuveen LLC purchased a new position in shares of Hims & Hers Health in the 1st quarter valued at about $58,403,000. BIT Capital GmbH boosted its stake in shares of Hims & Hers Health by 7.4% in the 1st quarter. BIT Capital GmbH now owns 1,642,493 shares of the company’s stock valued at $48,536,000 after buying an additional 112,949 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Hims & Hers Health by 1.2% in the 1st quarter. Bank of New York Mellon Corp now owns 1,260,292 shares of the company’s stock valued at $37,242,000 after buying an additional 15,339 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Zacks Research cut Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Hims & Hers Health in a research note on Tuesday. UBS Group set a $30.00 price objective on Hims & Hers Health in a research note on Monday, June 23rd. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a research note on Friday, September 12th. Two investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $38.92.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the transaction, the insider owned 169,940 shares of the company’s stock, valued at $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total value of $33,382,800.00. Following the transaction, the chief executive officer directly owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. This trade represents a 22.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,561,799 shares of company stock valued at $80,686,085 over the last quarter. Company insiders own 13.71% of the company’s stock.

Hims & Hers Health Price Performance

HIMS stock opened at $59.12 on Friday. The business has a 50 day moving average price of $51.05 and a 200 day moving average price of $48.63. The stock has a market cap of $13.36 billion, a price-to-earnings ratio of 73.90, a PEG ratio of 4.29 and a beta of 2.25. Hims & Hers Health, Inc. has a fifty-two week low of $18.33 and a fifty-two week high of $72.98. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company’s quarterly revenue was up 72.6% on a year-over-year basis. During the same period last year, the firm earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.